Curated News
By: NewsRamp Editorial Staff
September 10, 2026
Helus Pharma CEO to Speak at Morgan Stanley Healthcare Conference
TLDR
- Helus Pharma CEO presents at Morgan Stanley conference, offering investors a chance to gain an edge on the company's depression and anxiety treatments.
- The fireside chat webcast on Sept. 16 details Helus Pharma's clinical progress for HLP003 and HLP004 in treating major depressive and anxiety disorders.
- Helus Pharma aims to help minds heal by developing novel serotonergic agonists that could provide durable mental health improvements for depression and anxiety sufferers.
- Helus Pharma, trading as HELP, is developing synthetic molecules to activate serotonin pathways and promote neuroplasticity for mental health conditions.
Impact - Why it Matters
This news matters because Helus Pharma is at the forefront of developing novel serotonergic agonists, a new class of synthetic molecules that could transform the treatment of depression and anxiety. With its lead candidate, HLP003, already in Phase 3 trials for major depressive disorder and holding Breakthrough Therapy Designation from the FDA, the company is well-positioned to address the significant unmet need in mental health care. The fireside chat at the Morgan Stanley Global Healthcare Conference provides a platform for CEO Michael Halstead to share the company’s vision and progress with a broad audience of investors and industry experts. As mental health issues continue to rise globally, innovative treatments like those being developed by Helus Pharma could offer new hope for patients who have not responded to existing therapies. Moreover, the event shines a spotlight on the potential of psychedelic-inspired medicines, which are gaining traction in the pharmaceutical industry. For investors, this is an opportunity to gain insights into a company that is pushing the boundaries of neuroscience and could potentially deliver substantial returns if its therapies succeed. The widespread dissemination of this news through BioMedWire and its network ensures that stakeholders are well-informed about Helus Pharma’s latest developments.
Summary
Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., has announced that CEO Michael Halstead will take part in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The session is scheduled for Sept. 16 at 8:30 a.m. EDT and will be webcast live, with a replay accessible on the Events & Presentations page of Helus Pharma’s investor relations website. The announcement was disseminated on behalf of Helus Pharma and may include paid advertising.
Founded in 2019, Helus Pharma is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. Its lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another proprietary NSA, HLP004, is in Phase 2 for generalized anxiety disorder. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram.
The full press release is available at https://ibn.fm/r0jfC. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP. This announcement is powered by BioMedWire, a specialized communications platform focused on the Biotechnology (BioTech), Biomedical Sciences (BioMed), and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma CEO to Speak at Morgan Stanley Healthcare Conference
